Diligence memo · auto-generated · as of July 2, 2026
Reprogram Biosciences, Inc.
Reprogram Biosciences, Inc. looks over-valued against its niche peers and is active on financing cadence.
Businessfiled
Reprogram Biosciences, Inc. operates in Biotechnology, based in San Francisco.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Reprogram Biosciences, Inc. has raised $1.0M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $1.0M on 2025-05-09.
Most recent recorded round closed around 2025-05-09.
Valuation (modeled)modeled
Provath models Reprogram Biosciences, Inc. at approximately $2.7M (range $533K–$7.1M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.83× the median modeled value of Pre-Seed Biotechnology companies in 2025–2027 (79 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 14 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 19% of Biotechnology peers (4293 compared).
Modeled value ranks above 6% of those peers.
Closest niche peers: Illexcor Holdings, LLC, Maxymune Therapeutics, Inc., EnZeta Immunotherapies, Inc., Eliaz Therapeutics Inc., Mekiri Bio, Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.